SC
ANIX icon

Steven Cohen’s Anixa Biosciences ANIX Stock Holding History

Steven Cohen’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,276
Closed -$44.6K – 3972
2026
Q1 		$44.6K Sell
17,276
-13,780
-44% -$40.8K ﹤0.01% 3666
2025
Q4 		$96.9K Buy
+31,056
New +$127K ﹤0.01% 3742

Other funds holding ANIX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Steven Cohen's ANIX Position: Q2 2026 in Review

Steven Cohen sold out of Anixa Biosciences (ANIX) in Q2 2026, closing a stake of 17,276 shares — an estimated $44.6K sold.

Steven Cohen first reported a position in ANIX in Q4 2025 and held it in 2 quarters. The position peaked at $96.9K in Q4 2025. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

  • Steven Cohen reported no remaining Anixa Biosciences position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 17,276 Anixa Biosciences shares in Q2 2026, an estimated $44.6K.
  • Steven Cohen first reported a position in Anixa Biosciences in Q4 2025 and held it in 2 quarters.
  • Steven Cohen's Anixa Biosciences position peaked at $96.9K in Q4 2025.
  • 62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.